Reneo_Update_Inline_RGB_REGISTERED_OTL_GREY_TP.jpg
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
May 07, 2024 07:35 ET | Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
Intra-Cellular_Logo_RGB_ALT.jpg
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
May 07, 2024 07:30 ET | Intra-Cellular Therapies Inc.
CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53% increase CAPLYTA’s strong prescription uptake continues: Q1 2024...
dave_logo_2022@4x (1).png
Dave Reports Record First Quarter 2024 Results
May 07, 2024 07:30 ET | Dave Operating LLC
Record Q1 Revenue of $73.6 Million; Y/Y Revenue Growth Accelerates for Second Consecutive Quarter Q1 GAAP Net Income Reaches $34.2 Million and Adj. EBITDA Increases to $13.2 Million Dave Raises 2024...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
May 07, 2024 07:30 ET | Cognition Therapeutics, Inc.
- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected Mid-2024 -- SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants - PURCHASE, N.Y., May 07,...
ihl_logo.png
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
May 07, 2024 07:30 ET | Incannex Healthcare
MELBOURNE, Australia and NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Corporation to Present at Upcoming May Investor Conferences
May 07, 2024 07:30 ET | Repligen Corporation
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
iSpecimen Logo.png
iSpecimen Reports First Quarter 2024 Results
May 07, 2024 07:30 ET | iSpecimen Inc
iSpecimen Reports First Quarter 2024 Results
Invivyd logo_
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
May 07, 2024 07:30 ET | Invivyd
Pathway leverages immunobridging approach via serum virus neutralizing antibody (sVNA) titers enabled by prior successful COVID-19 treatment clinical trial “STAMP” conducted with prototype antibody...
Altimmune logo.png
Altimmune to Participate at Two Upcoming Investor Conferences
May 07, 2024 07:30 ET | Altimmune, Inc
GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
20.06.Amesite.Color.Logo.jpg
Amesite Announces Strategic Five-Year Partnership with Franciscan Missionaries of Our Lady University to Deliver Healthcare Training for Healthcare Professionals
May 07, 2024 07:30 ET | Amesite Inc.  
DETROIT, May 07, 2024 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets,...